期刊文献+

盐酸度洛西汀肠溶胶囊的制备与比格犬体内动力学评价 被引量:3

Duloxetine hydrochloride enteric release capsules: preparation and pharmacokinetic evaluation in beagle dogs
下载PDF
导出
摘要 目的 以空白丸芯为载体、醋酸羟丙甲纤维素琥珀酸酯为包衣材料制备盐酸度洛西汀肠溶微丸胶囊,并以市售参比制剂欣百达对照进行犬体内药动学研究。方法 采用底喷流化床包衣技术进行载药和包衣,制备盐酸度洛西汀肠溶微丸,分别采用扫描电镜、溶出度与释放度测定法对自制和参比制剂的结构和释放行为进行对比。采用LC-MS/MS法测定自制和参比制剂在犬体内药动学。结果 自制和参比制剂结构近似,包衣增重为20%的自制制剂与参比制剂释放曲线的f相似因子为75,释放曲线相似。两制剂的AUC和AUC的统计结果等效,表明两制剂在犬体内的药物吸收程度基本一致。c参数的个体内变异系数较大导致统计结果超出了规定范围。结论 自制制剂与参比制剂欣百达体外释放行为一致,比格犬体内具有相似的药时曲线。 Objective To prepare duloxetine hydrochloride enteric release capsules and to study pharmacokinetic profile in dogs with Cymbalta as reference.Methods The Wurster fluid bed with bottom spray was used to prepare duloxetine hydrochloride enteric release pellets.The SEM and in vitro dissolution tests were performed to evaluate the microstructure and drug release behavior of home-made dosage form and Cymbalta.The LC-MS/MS method was developed to study the pharmacokinetic profile of home-made dosage form and Cymbalta.Results The home-made dosage forms showed similar microstructure with Cymbalta.The home-made dosage forms at 20% coating weight gain showed similarity factor(f) of 75,indicating the similar in vitro release profiles.The home-made dosage form showed comparable absorption extent with Cymbalta as characterized by the bioequivalent AUCand AUC.The statistics of cwas beyond the acceptance range due to the large variation coefficient and small subjects.Conclusion The home-made dosage form demonstrated similar in vitro release behavior and pharmacokinetics curve with Cymbalta in beagle dogs.
作者 王嘉平 熊晓崴 常琦 乔明曦 WANG Jiaping;XIONG Xiaowei;CHANG Qi;QIAO Mingxi(School of Pharmacy,Shenyang Pharmaceutical University,Shenyang 110016,China;Yantai Luyin Pharmaceuical Co.Ltd.Yantai 264000,China)
出处 《沈阳药科大学学报》 CAS CSCD 北大核心 2022年第8期899-905,共7页 Journal of Shenyang Pharmaceutical University
关键词 盐酸度洛西汀 肠溶微丸 流化床 包衣 药动学 duloxetine hydrochloride enteric release capsule fluid bed coating pharmacokinetics
  • 相关文献

参考文献3

二级参考文献20

  • 1白志华,方晓玲.难溶性药物的口服制剂研究进展[J].中国药学杂志,2005,40(15):1124-1127. 被引量:21
  • 2邵仲英,徐巧玲,史爱欣.新型5-羟色胺和去甲肾上腺素再摄取抑制剂——度洛西汀[J].中国全科医学,2006,9(10):823-825. 被引量:9
  • 3张璐璐,郑洪波.盐酸度洛西汀介绍[J].临床精神医学杂志,2007,17(4):284-285. 被引量:34
  • 4国家食品药品监督管理局.化学药物稳定性研究技术指导原则[S].2005.3. 被引量:3
  • 5Detke M J, Lu Y, Goldstein DJ, et al. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression [ J]. Journal of Psychiatric Research, 2002,36: 383-390. 被引量:1
  • 6Detke MJ,Lu Y, Goldstein DJ, et al. Duloxetine, 60rag daily, for major depressive disorder: a randomized double-blind placebo con- trolled trim [J]. J Clin Psychiatry, 2002, 63(4) : 308-315. 被引量:1
  • 7Hunziker ME, Suehs BT, bettinger TL, et al. Duloxetine Hydrochlo- ride: A New Dual-Acting Medication for the Treatment of Major De- pressive Disorder [ J ]. Clinical Therapeutics, 2005, 27 ( 8 ) : 1126- 1143. 被引量:1
  • 8Sinha VR, Kumria R, Bhinge JR. Stress degradation studies on du- loxetine hydrochloride and development of an RP-HPLC method for its determination in capsule formulation [ J ]. J Chromatogr Sci, 2009, 47(5) : 589-593. 被引量:1
  • 9Jansen PJ, Kemp CA, Maple SR, et al. Characterization of impurities formed by interaction of duloxetine HCI with enteric polymers hydroxypropyl methylcellulose acetate suceinate and hydroxypropyl methylcellulose phthalate [J]. J Pharm Sci, 1998, 87( 1 ) : 81-85. 被引量:1
  • 10Lecomte F, Siepmann J, Walther M, et al. Ploymer blends used for the aqueous coating of solid dosage forms:importance of the type of plasticizer [J]. J Control Ralease, 2004, 99(1) : 1-13. 被引量:1

共引文献8

同被引文献33

引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部